ATE414701T1 - Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren - Google Patents

Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren

Info

Publication number
ATE414701T1
ATE414701T1 AT04789404T AT04789404T ATE414701T1 AT E414701 T1 ATE414701 T1 AT E414701T1 AT 04789404 T AT04789404 T AT 04789404T AT 04789404 T AT04789404 T AT 04789404T AT E414701 T1 ATE414701 T1 AT E414701T1
Authority
AT
Austria
Prior art keywords
protein kinase
kinase inhibitor
binding assay
fluorescence probe
inhibitor binding
Prior art date
Application number
AT04789404T
Other languages
English (en)
Inventor
Anthony S Prokopowicz
Martha Priscilla Brown
Jessi Jones-Wildeson
Scott Jakes
Mark E Labadia
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE414701T1 publication Critical patent/ATE414701T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B11/00—Diaryl- or thriarylmethane dyes
    • C09B11/04—Diaryl- or thriarylmethane dyes derived from triarylmethanes, i.e. central C-atom is substituted by amino, cyano, alkyl
    • C09B11/10—Amino derivatives of triarylmethanes
    • C09B11/24—Phthaleins containing amino groups ; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B55/00—Azomethine dyes
    • C09B55/002—Monoazomethine dyes
    • C09B55/003—Monoazomethine dyes with the -C=N- group attached to an heteroring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04789404T 2003-10-03 2004-09-30 Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren ATE414701T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50853903P 2003-10-03 2003-10-03

Publications (1)

Publication Number Publication Date
ATE414701T1 true ATE414701T1 (de) 2008-12-15

Family

ID=34421754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04789404T ATE414701T1 (de) 2003-10-03 2004-09-30 Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren

Country Status (8)

Country Link
US (2) US7125996B2 (de)
EP (1) EP1670789B1 (de)
JP (1) JP4949845B2 (de)
AT (1) ATE414701T1 (de)
CA (1) CA2541059C (de)
DE (1) DE602004017884D1 (de)
ES (1) ES2315713T3 (de)
WO (1) WO2005033330A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4324480B2 (ja) * 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
UY28526A1 (es) * 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
PE20060776A1 (es) * 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas
WO2007057397A1 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer
EE200600030A (et) * 2006-08-15 2008-04-15 Tartu �likool Proteiinkinaasi fluorestsents-sond
MX2009005264A (es) * 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
WO2009097318A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company A fluorescence polarization binding assay for characterizing glucokinase ligands
DK2300472T3 (da) * 2008-06-06 2012-04-10 Boehringer Ingelheim Int Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
US8735444B2 (en) 2009-06-26 2014-05-27 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Fluorinated rhodamines as photostable fluorescent dyes for labelling and imaging techniques
EP2482072B1 (de) 2011-01-26 2016-07-06 University of Tartu Photolumineszierenden sonde
EP2700946A1 (de) 2012-08-24 2014-02-26 University of Tartu Bisubstratfluoreszente Sonden für Proteinkinase CK2
CN114292281B (zh) * 2021-12-22 2023-10-24 东南大学 一种用于实现细胞内脂滴动态成像的小分子荧光探针及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06172312A (ja) * 1992-03-04 1994-06-21 Wako Pure Chem Ind Ltd 1級アミノ基を有する化合物の蛍光標識化方法
JP3851706B2 (ja) * 1996-05-20 2006-11-29 日清紡績株式会社 蛍光性基含有カルボジイミド化合物
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US6169106B1 (en) * 1998-04-15 2001-01-02 Boehringer Ingelheim Pharma Kg Indolinones having kinase inhibitory activity
CN1319090A (zh) * 1998-09-25 2001-10-24 贝林格尔英格海姆法玛公司 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
US6872533B2 (en) * 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
JP4460292B2 (ja) * 2001-10-17 2010-05-12 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
EP1590334B1 (de) * 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen

Also Published As

Publication number Publication date
CA2541059A1 (en) 2005-04-14
EP1670789B1 (de) 2008-11-19
JP4949845B2 (ja) 2012-06-13
ES2315713T3 (es) 2009-04-01
US7125996B2 (en) 2006-10-24
EP1670789A2 (de) 2006-06-21
US7588899B2 (en) 2009-09-15
JP2007509845A (ja) 2007-04-19
WO2005033330A3 (en) 2005-07-28
WO2005033330A2 (en) 2005-04-14
DE602004017884D1 (de) 2009-01-02
US20050100978A1 (en) 2005-05-12
CA2541059C (en) 2013-09-17
US20060263841A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
DE602005023529D1 (de) Homogener nachweis von analyten
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
TW200741010A (en) Method for predicting the response to a treatment
WO2008021290A3 (en) Organ-specific proteins and methods of their use
DE60331345D1 (de) Probensubstrat zur biologischen untersuchung
NO20074389L (no) Bestemmelse av respondere til kjemoterapi
WO2007114986A3 (en) Cooperative probes and methods of using them
ATE554106T1 (de) Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
DE60129008D1 (de) Methode zur identifizierung von regulatoren der bildung von protein-age-derivaten
CY1115640T1 (el) Διαγνωση και αγωγη εναντι της σχιζοφρενειας
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
ATE404692T1 (de) Screening-verfahren zur identifizierung von tau- protein modulierenden substanzen.
WO2004077021A3 (en) Standardized evaluation of therapeutic efficacy based on cellular biomarkers
DE60331857D1 (de) Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
ATE345397T1 (de) Verfahren zur isolierung von bakterien aus biologischen proben
ATE476440T1 (de) Hybridisierung von pna-sonden in alkohollösungen
DE60221550D1 (de) Methode zur bestimmung der zellzyklusposition
TW200508936A (en) The establishment of proteome structure profile databases and their uses
DE60025336D1 (de) Verfahren und kit zur früherkennung von krebs
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
WO2010006616A3 (en) Method and kit for examination of cells using n-(9-acridinyl)maleimide (nam) or using 7-diethylamino-3-((4'-(iodoacetyl)amino)phenyl)-4-methylcoumarin (cpi)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1670789

Country of ref document: EP